Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0OR5P
|
|||
| Former ID |
DNCL002622
|
|||
| Drug Name |
TAS-106
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Head and neck cancer [ICD-11: 2D42] | Phase 2 | [1] | |
| Company |
Taiho Pharma U.S.A.
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H13N3O5
|
|||
| Canonical SMILES |
C#CC1(C(OC(C1O)N2C=CC(=NC2=O)N)CO)O
|
|||
| InChI |
1S/C11H13N3O5/c1-2-11(18)6(5-15)19-9(8(11)16)14-4-3-7(12)13-10(14)17/h1,3-4,6,8-9,15-16,18H,5H2,(H2,12,13,17)/t6-,8+,9-,11-/m1/s1
|
|||
| InChIKey |
JFIWEPHGRUDAJN-DYUFWOLASA-N
|
|||
| CAS Number |
CAS 180300-43-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mycobacterium RNA polymerase (MycB RNAP) | Target Info | Modulator | [2] |
| KEGG Pathway | Purine metabolism | |||
| Pyrimidine metabolism | ||||
| Metabolic pathways | ||||
| RNA polymerase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00737360) Phase II Study of TAS-106 to Treat Head and Neck Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.Invest New Drugs.2012 Feb;30(1):316-26. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.